feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: JAMA Network Open, American Medical Association (AMA), Vol. 6, No. 8 ( 2023-08-14), p. e2328828-
    Abstract: Ginkgo diterpene lactone meglumine (GDLM) has attracted much attention because of its potential neuroprotective properties in ischemic stroke. The efficacy of GDLM in patients with acute ischemic stroke (AIS) needs to be verified by well-designed randomized clinical trials. Objective To assess the efficacy and safety of GDLM in patients with AIS. Design, Setting, and Participants This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial involved 3448 patients who had AIS, were aged 18 to 80 years, had a clinically diagnosed AIS symptom within 48 hours of onset, had a modified Rankin Scale (mRS) score of 0 or 1 prior to onset, and had a National Institutes of Health Stroke Scale score ranging from 4 to 24. The trial took place at 100 centers in China from February 1, 2016, to May 1, 2018. The mRS is a global stroke disability scale with scores ranging from 0 (no symptoms or completely recovered) to 6 (death). The National Institutes of Health Stroke Scale is a tool used by clinicians to quantify impairment caused by stroke (range, 0-42, with higher scores indicating greater severity). Data were analyzed from January 2019 to December 2022. Interventions Patients were randomized to receive GDLM or placebo once daily via intravenous infusion in a 1:1 ratio. The treatment was dispensed within 48 hours after symptoms and continued for 14 days. Interventions of thrombolysis and thrombectomy were not permitted during the treatment. Main Outcomes and Measures The primary outcome was the proportion of patients with an mRS of 0 or 1 on day 90 after randomization. Safety outcomes included adverse events and serious adverse events. Results A total of 3448 patients were randomized, with 1725 patients assigned to the GDLM group and 1723 patients assigned to the placebo group. The median (IQR) age of the patients was 63 (55-71) years, and 1232 (35.7%) were women. The primary outcome on day 90 occurred in 877 patients (50.8%) in the GDLM group, and 759 patients (44.1%) in the placebo group (risk difference, 6.79%; 95% CI, 3.46%-10.10%; odds ratio, 1.31; 95% CI, 1.15-1.50; relative risk, 1.15; 95% CI, 1.08-1.24; P   & amp;lt; .001). Adverse events occurred relatively equally between the 2 groups (303 [17.6%] vs 298 [17.3%] ; risk difference, 0.27%; 95% CI, −2.26% to 2.80%; odds ratio, 1.02; 95% CI, 0.85-1.21; relative risk, 1.02; 95% CI, 0.88-1.17; P  = .83). Conclusions and Relevance Among patients with AIS in this randomized clinical trial, GDLM improved the proportion of patients achieving favorable clinical outcomes at 90 days compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT02526225
    Type of Medium: Online Resource
    ISSN: 2574-3805
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2023
    detail.hit.zdb_id: 2931249-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2019
    In:  Current Organic Chemistry Vol. 23, No. 15 ( 2019-10-28), p. 1663-1670
    In: Current Organic Chemistry, Bentham Science Publishers Ltd., Vol. 23, No. 15 ( 2019-10-28), p. 1663-1670
    Abstract: Protein methylation is an important and reversible post-translational modification that regulates many biological processes in cells. It occurs mainly on lysine and arginine residues and involves many important biological processes, including transcriptional activity, signal transduction , and the regulation of gene expression. Protein methylation and its regulatory enzymes are related to a variety of human diseases, so improved identification of methylation sites is useful for designing drugs for a variety of related diseases. In this review, we systematically summarize and analyze the tools used for the prediction of protein methylation sites on arginine and lysine residues over the last decade.
    Type of Medium: Online Resource
    ISSN: 1385-2728
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2019
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Food Hydrocolloids, Elsevier BV, Vol. 110 ( 2021-01), p. 106159-
    Type of Medium: Online Resource
    ISSN: 0268-005X
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2026957-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Elsevier BV ; 2019
    In:  Innovative Food Science & Emerging Technologies Vol. 56 ( 2019-08), p. 102181-
    In: Innovative Food Science & Emerging Technologies, Elsevier BV, Vol. 56 ( 2019-08), p. 102181-
    Type of Medium: Online Resource
    ISSN: 1466-8564
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2019
    detail.hit.zdb_id: 2025032-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Water, MDPI AG, Vol. 12, No. 11 ( 2020-11-20), p. 3256-
    Abstract: Phaeocystis globosa is regarded as a notoriously harmful algal bloom species. Suppressing harmful algae using algicidal substances extracted from plants is considered an effective method. The physiological and biochemical processes of P. globosa were explored by exposure to different concentrations of aqueous extracts of Cyperus rotundus. All treatments indicated various inhibitory effects on the algal growth compared to the control samples without adding extracts. At 48 h, the 4, 8, and 16 mg/mL treatment groups showed a significant inhibitory effect, consistent with a decrease in the chlorophyll-a content and photosynthetic efficiency. The images of the transmission electron microscope (TEM) further confirmed that a subset of the cells in the treatment groups exhibited morphological anomalies. The algicidal active substances were mainly identified as phenolic acids containing maximal content of quinic acid in aqueous extracts according to the results of ultra-high-performance liquid chromatography-tandem time-of-flight mass spectrometer (UPLC-HRMS). The 50% anti-algal effect concentration of quinic acid was 22 mg/L at 96 h (EC50–96h). Thus, the phenolic acids might be considered as major inhibitors of the growth of P. globosa. These results demonstrated that the aqueous extracts of C. rotundus could potentially control the growth of P. globosa.
    Type of Medium: Online Resource
    ISSN: 2073-4441
    Language: English
    Publisher: MDPI AG
    Publication Date: 2020
    detail.hit.zdb_id: 2521238-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Frontiers Media SA ; 2019
    In:  Frontiers in Bioengineering and Biotechnology Vol. 7 ( 2019-9-4)
    In: Frontiers in Bioengineering and Biotechnology, Frontiers Media SA, Vol. 7 ( 2019-9-4)
    Type of Medium: Online Resource
    ISSN: 2296-4185
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2019
    detail.hit.zdb_id: 2719493-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Hindawi Limited ; 2022
    In:  Computational and Mathematical Methods in Medicine Vol. 2022 ( 2022-8-27), p. 1-6
    In: Computational and Mathematical Methods in Medicine, Hindawi Limited, Vol. 2022 ( 2022-8-27), p. 1-6
    Abstract: Epilepsy is a chronic noninfectious disease caused by sudden abnormal discharge of brain neurons, which leads to intermittent brain dysfunction. It is also one of the most common neurological diseases in the world. The automatic detection of epilepsy based on electroencephalogram through machine learning, correlation analysis, and temporal-frequency analysis plays an important role in epilepsy early warning and automatic recognition. In this study, we propose a method to realize EEG epilepsy recognition by means of triple genetic antagonism network (GAN). TripleGAN is used for EEG temporal domain, frequency domain, and temporal-frequency domain, respectively. The experiment was conducted through CHB-MIT datasets, which operated at the latest level in the same industry in the world. In the CHB-MIT dataset, the classification accuracy, sensitivity, and specificity exceeded 1.19%, 1.36%, and 0.27%, respectively. The crossobject ratio exceeded 0.53%, 2.2%, and 0.37%, respectively. It shows that the established deep learning model of TripleGAN has a good effect on EEG epilepsy classification through simulation and classification optimization of real signals.
    Type of Medium: Online Resource
    ISSN: 1748-6718 , 1748-670X
    Language: English
    Publisher: Hindawi Limited
    Publication Date: 2022
    detail.hit.zdb_id: 2256917-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2020
    In:  Current Pharmaceutical Design Vol. 26, No. 26 ( 2020-08-11), p. 3069-3075
    In: Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 26, No. 26 ( 2020-08-11), p. 3069-3075
    Abstract: With the continuous development of artificial intelligence (AI) technology, big data-supported AI technology with considerable computer and learning capacity has been applied in diagnosing different types of diseases. This study reviews the application of expert systems, neural networks, and deep learning used by AI technology in disease diagnosis. This paper also gives a glimpse of the intelligent diagnosis and treatment of digestive system diseases, respiratory system diseases, and osteoporosis by AI technology.
    Type of Medium: Online Resource
    ISSN: 1381-6128
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2020
    SSG: 15,3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Frontiers Media SA ; 2021
    In:  Frontiers in Genetics Vol. 12 ( 2021-10-21)
    In: Frontiers in Genetics, Frontiers Media SA, Vol. 12 ( 2021-10-21)
    Abstract: Significant genetic association exists between rheumatoid arthritis (RA) and cardiovascular disease. The associated mechanisms include common inflammatory mediators, changes in lipoprotein composition and function, immune responses, etc. However, the causality of RA and vascular/heart problems remains unknown. Herein, we performed Mendelian randomization (MR) analysis using a large-scale RA genome-wide association study (GWAS) dataset (462,933 cases and 457,732 controls) and six cardio-cerebrovascular disease GWAS datasets, including age angina (461,880 cases and 447,052 controls), hypertension (461,880 cases and 337,653 controls), age heart attack (10,693 cases and 451,187 controls), abnormalities of heartbeat (461,880 cases and 361,194 controls), stroke (7,055 cases and 454,825 controls), and coronary heart disease (361,194 cases and 351,037 controls) from United Kingdom biobank. We further carried out heterogeneity and sensitivity analyses. We confirmed the causality of RA with age angina (OR = 1.17, 95% CI: 1.04–1.33, p = 1.07E−02), hypertension (OR = 1.45, 95% CI: 1.20–1.75, p = 9.64E−05), age heart attack (OR = 1.15, 95% CI: 1.05–1.26, p = 3.56E−03), abnormalities of heartbeat (OR = 1.07, 95% CI: 1.01–1.12, p = 1.49E−02), stroke (OR = 1.06, 95% CI: 1.01–1.12, p = 2.79E−02), and coronary heart disease (OR = 1.19, 95% CI: 1.01–1.39, p = 3.33E−02), contributing to the understanding of the overlapping genetic mechanisms and therapeutic approaches between RA and cardiovascular disease.
    Type of Medium: Online Resource
    ISSN: 1664-8021
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2021
    detail.hit.zdb_id: 2606823-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Frontiers Media SA ; 2019
    In:  Frontiers in Bioengineering and Biotechnology Vol. 7 ( 2019-9-18)
    In: Frontiers in Bioengineering and Biotechnology, Frontiers Media SA, Vol. 7 ( 2019-9-18)
    Type of Medium: Online Resource
    ISSN: 2296-4185
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2019
    detail.hit.zdb_id: 2719493-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages